Psilocybin (Diamond Therapeutics)

赛洛西宾 (Diamond Therapeutics)

Report date: 2025/06/13 20:00:59

Base Information

Drug NamePsilocybin (Diamond Therapeutics)
Drug Alias NameLow-dose psilocybin
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionSerotonin 1a (5-HT1a) receptor agonistsSerotonin 2a (5-HT2a) receptor agonists
TargetsSerotonin 1a (5-HT1a) receptorSerotonin 2a (5-HT2a) receptor
Therapy Area/IndicationsAnxiety DisordersMental Disorders
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCanadaUnited States
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesDiamond Therapeutics Inc
China Registration ClassN/A

Develop Information

Active CompaniesQueen'S UniversityDiamond Therapeutics Inc
Inactive CompaniesN/A
Active IndicationsAnxiety DisordersMental Disorders
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A